4 March 2013Big Pharma

India rejects Bayer plea over compulsory licence

India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Bayer takes another swipe at Nexavar compulsory licence

15 October 2013 Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

Bayer’s compulsory licence appeal set to start in India

29 October 2013 A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

More on this story

Bayer takes another swipe at Nexavar compulsory licence

15 October 2013 Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

Bayer’s compulsory licence appeal set to start in India

29 October 2013 A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

More on this story

Bayer takes another swipe at Nexavar compulsory licence

15 October 2013 Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

Bayer’s compulsory licence appeal set to start in India

29 October 2013 A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

More features

Gene tech firm fends off injunction in test kit dispute

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve